Clinical Trial Update: Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) [Phase 2]

View source ↗

Summary

An ongoing Phase 2 trial (ADAPT Lung) evaluating adaptive adjuvant sintilimab therapy guided by minimal residual disease in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: NSCLC (Non-small Cell Lung Cancer), MRD | Phase 2 | Status: RECRUITING